Catalent Completes $25 Million Expansion of Its Clinical Supply Facility in Schorndorf, Germany

Expansion adds more temperature-controlled storage and dedicated space for FastChain demand-led supply service Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments

Businesswire02:00 ET

Catalent Price Target Maintained With a $63.50/Share by RBC Capital

Catalent Price Target Maintained With a $63.50/Share by RBC

Dow JonesJul 11 11:10 ET

RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

BenzingaJul 11 11:00 ET

RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5

RBC Capital analyst Sean Dodge maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 39.3% and a

Moomoo NewsJul 11 07:34 ET · Ratings

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)

TipRanksJul 11 06:40 ET

Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC

(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.

The Edge MarketsJul 10 05:29 ET